Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
3 buyers bought $400K
0 sellers sold $0
Open-market · last 90 days:
3 buyers bought $400K
0 sellers sold $0
| Insider | Role | Date | Transaction | Shares | Value |
|---|
| Epstein David R |
Director |
2026-10-21 |
Open-market buy |
5000 |
$44K |
| Epstein David R |
Director |
2026-10-21 |
Open-market buy |
5000 |
$44K |
| Epstein David R |
Director |
2026-10-08 |
Open-market buy |
5000 |
$44K |
| Epstein David R |
Director |
2026-10-06 |
Open-market buy |
5000 |
$44K |
| Kemula Pierre Thadee Victor |
Chief Financial Officer |
2026-10-06 |
Open-market buy |
3000 |
$26K |
| Kemula Pierre Thadee Victor |
Chief Financial Officer |
2026-10-06 |
Open-market buy |
5000 |
$43K |
| Kemula Pierre Thadee Victor |
Chief Financial Officer |
2026-10-06 |
Open-market buy |
2000 |
$17K |
| Knotnerus Tim Jasper |
Chief Executive Officer, Director |
2026-10-06 |
Open-market buy |
5000 |
$44K |
| Epstein David R |
Director |
2026-10-05 |
Open-market buy |
5000 |
$43K |
| Knotnerus Tim Jasper |
Chief Executive Officer, Director |
2026-10-05 |
Open-market buy |
6000 |
$51K |
Most recent 10 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
6-K
filed 2026-09-14
confidence 85%
EX-99.1
This press release announces positive Phase 1 clinical trial results for AGMB-447 in IPF patients, including favorable safety/tolerability, robust target engagement, and the design and planned initiation of a Phase 2 study (INSPIRIA). While the company is clinical-stage and this represents a material clinical milestone advancing the lead program, it does not fit the discrete event categories (not an earnings release, M&A, executive change, or financial obligation). The disclosure is clearly operational—a clinical development milestone—but the specific type is not enumerated, making `operational_other` the appropriate classification.
View raw filing on EDGAR →
6-K
filed 2026-09-11
confidence 95%
EX-99.1
The exhibit announces shareholder approval of the appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of Agomab's Board of Directors at the Company's Special and Extraordinary General Shareholders' Meeting on September 11, 2026. This is a discrete executive appointment event requiring disclosure under Item 5.02 of Form 8-K (or equivalent 6-K disclosure). Board appointments are material to investors as they affect governance and strategic direction.
View raw filing on EDGAR →
6-K
filed 2026-08-10
confidence 95%
EX-99.1
Agomab Therapeutics announced the proposed appointments of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors, to be submitted for shareholder approval at a Special General Meeting on September 11, 2026. Both candidates bring significant industry experience in biotechnology leadership and clinical development, directly relevant to the company's strategic direction.
View raw filing on EDGAR →
6-K
filed 2026-06-23
confidence 85%
EX-99.1
This press release announces the design and regulatory alignment of a Phase 2b clinical trial (NOV-ERA study) for ontunisertib in fibrostenosing Crohn's disease, including FDA alignment on primary endpoints, protocol submission to regulatory agencies, and expected study initiation in H2 2026. This is a material operational/clinical development milestone for a clinical-stage biopharmaceutical company, representing significant progress in late-stage development of a key product candidate, but does not fit the discrete event categories (earnings, M&A, executive changes, etc.) and is best classified as an operational milestone.
View raw filing on EDGAR →